Shuttle Pharmaceuticals shares are trading higher after the company was granted #12077515 for selective histone deacetylase inhibitors.
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals shares rose following the grant of patent #12077515 for their selective histone deacetylase inhibitors.
September 03, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharmaceuticals' stock price increased due to the granting of a new patent for their selective histone deacetylase inhibitors, which could enhance their product offerings and market position.
The granting of a patent is a significant milestone for biotech companies as it protects their intellectual property and can lead to future revenue streams. This news likely increased investor confidence, leading to a rise in SHPH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100